Brinker Capital Investments, LLC Summit Therapeutics Inc. Transaction History
Brinker Capital Investments, LLC
- $11.4 Billion
- Q3 2025
A detailed history of Brinker Capital Investments, LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Brinker Capital Investments, LLC holds 20,278 shares of SMMT stock, worth $369,870. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,278
Previous 52,964
61.71%
Holding current value
$369,870
Previous $1.13 Million
62.73%
% of portfolio
0.0%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding SMMT
# of Institutions
264Shares Held
93.6MCall Options Held
4.72MPut Options Held
4.03M-
Baker Bros. Advisors LP New York, NY33.7MShares$615 Million5.7% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$208 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$144 Million0.0% of portfolio
-
State Street Corp Boston, MA6.36MShares$116 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.54MShares$82.8 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.67B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...